IMRE CORP
8-K, 1996-01-29
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: COPYTELE INC, 10-K405, 1996-01-29
Next: STERLING SOFTWARE INC, 10-K/A, 1996-01-29



<PAGE>
                       SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C.  20549

                                 ---------------



                                    FORM 8-K

                                 CURRENT REPORT




                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934



Date of Report (Date of earliest event reported)                Not Applicable
                                                               -----------------

                                IMRE CORPORATION
             ------------------------------------------------------
             (Exact name of registrant as specified in its charter)


                                    Delaware
                 ----------------------------------------------
                 (State or other jurisdiction of incorporation)



        0-12943                                          22-2389839
- ------------------------                      ---------------------------------
(Commission File Number)                      (IRS Employer Identification No.)


401 Queen Anne Avenue North
Seattle, Washington                                                        98109
- --------------------------------------------------------------------------------
(Address of principal executive offices)                              (Zip Code)

Registrant's telephone number, including area code (206) 298-9400



          -------------------------------------------------------------
          (Former name or former address, if changed since last report)


                                Page 1 of 3 Pages
                  No Exhibits Are Being Filed with this Form 8-K

<PAGE>

ITEM 5.  OTHER EVENTS

     The undersigned registrant hereby undertakes as follows, which undertaking
shall be incorporated by reference into the registrant's Registration Statement
on Form S-8 (Registration No. 33-20188) filed February 22, 1988:

     Insofar as indemnification for liabilities arising under the Securities
Act of 1933 may be permitted to directors, officers and controlling persons
of the registrant pursuant to the foregoing provisions, or otherwise, the
registrant has been advised that in the opinion of the Securities and
Exchange Commission such indemnification is against public policy as
expressed in the Act and is, therefore, unenforceable.  In the event that a
claim for indemnification against such liabilities (other than the payment by
the registrant of expenses incurred or paid by a director, officer or
controlling person of the registrant in the successful defense of any action,
suit or proceeding) is asserted by such director, officer or controlling
person in connection with the securities being registered, the registrant
will, unless in the opinion of its counsel the matter has been settled by
controlling precedent, submit to a court of appropriate jurisdiction the
question whether such indemnification by it is against public policy as
expressed in the Act and will be governed by the final adjudication of such
issue.


                                     Page 2

<PAGE>

SIGNATURES:

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
     registrant has duly caused this report to be signed on its behalf by the
     undersigned hereunto duly authorized.



                                             IMRE CORPORATION



    January 26, 1996                         By  /s/ Alex P. de Soto
- -------------------------                      -------------------------------
          Date                                 Alex P. de Soto
                                               Vice President,
                                               Chief Financial Officer, and
                                               Chief Accounting Officer


                                     Page 3


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission